Muscle-invasive and advanced bladder cancer

What changed: Muscle-invasive and advanced bladder cancer

Cancer page →

Every dated change on the records linked to Muscle-invasive and advanced bladder cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval2Trial result3Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMuscle-invasive and advanced bladder cancer
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026ApprovalDurvalumab
Durvalumab approved in US
High-risk NMIBC with BCG

2024 · 2

2023 · 2

2021 · 2

2019 · 1

2019MilestoneErdafitinib
Erdafitinib: first targeted drug for FGFR3-altered urothelial cancer
A milestone in how this cancer is treated.

2017 · 1

2017ApprovalDurvalumab
Durvalumab approved in US
Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021)

2016 · 1

2016MilestoneMuscle-invasive and advanced bladder cancer
Atezolizumab: first immunotherapy approval in bladder cancer
A milestone in how this cancer is treated.

2003 · 1

2003MilestoneCisplatin
Neoadjuvant MVAC improves survival before cystectomy (SWOG 8710)
A milestone in how this cancer is treated.

1985 · 1

1985MilestoneCisplatin
MVAC chemotherapy established for advanced disease
A milestone in how this cancer is treated.